Individualizing anaemia therapy
نویسنده
چکیده
Individualized strategies for managing renal anaemia with erythropoiesis-stimulating agents (ESAs) need to be advanced. Recent outcomes from clinical studies prompted a narrowing of the guideline-recommended haemoglobin target (11-12 g/dL) due to increased mortality and morbidity when targeting higher haemoglobin concentrations. Maintaining a narrow target is a clinical challenge, as haemoglobin concentration tends to fluctuate. The goal of individualized treatment is to achieve the haemoglobin target at the lowest ESA dose while avoiding significant fluctuations in haemoglobin concentrations and persistently low or high concentrations. This may require changes to the ESA dose and dosing frequency over the course of treatment.
منابع مشابه
Individualizing anaemia treatment: a discussion of case histories.
Current guidelines give evidence-based advice on how best to manage anaemia in patients with renal disease, but these guidelines do not consider individual patient needs, so tailoring anaemia management to each patient still remains a challenge for the treating physician. Two case studies are described that illustrate some of the key factors that need to be considered. The first case emphasizes...
متن کاملUsefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.
Ribavirin in combination with pegylated interferon alpha is the current standard treatment for chronic hepatitis C. Adequate exposure to ribavirin seems crucial for achieving the best virological response. However, anaemia is a frequent, dose-dependent limiting side effect of ribavirin use. Therefore, therapeutic drug monitoring of ribavirin plasma concentrations could be a useful tool for indi...
متن کاملMultiplexed Pharmacogenetic Assays for SNP Genotyping: Tools and Techniques for Individualizing Patient Therapy
متن کامل
Hepatitis B Virus Vaccination in Hemodialysis Patients: A Necessity for Individualizing of Immunization?
متن کامل
Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings
BACKGROUND Stavudine is no longer recommended as part of first-line therapy for patients initiating antiretroviral therapy (ART) in Uganda. Most patients are currently initiated on zidovudine-containing regimens, which can induce anaemia. We investigated the risk factors for early severe anaemia in the first six months of ART initiation. METHODS We defined baseline (ART initiation) anaemia as...
متن کامل